{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:46:42Z","timestamp":1782798402531,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunoglobulin G (IgG) type 4-related disease (IgG4-RD) is a rare, chronic fibroinflammatory condition that can affect multiple organ systems. Cutaneous involvement in IgG4-RD is even rarer. Moreover, the clinical manifestations of primary IgG4-related skin disease (IgG4-RSD) are often atypical, making it easy for clinicians to misdiagnose or overlook the condition, leading to delays in diagnosis and treatment.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Case presentation:<\/jats:bold>\n                      We report the case of a 36-year-old male who was admitted to the hospital due to recurrent papules and pustules at multiple sites across the body for 8 years. He was misdiagnosed with hidradenitis suppurativa at an outside hospital and received long-term anti-infective therapy and irregular prednisone treatment, but experienced recurrent episodes. This admission was prompted by worsening skin lesions complicated by sepsis. Based on clinical clues including chronic recurrent skin lesions, poor response to anti-infective therapy, and symptom relief with corticosteroids but frequent relapses, we performed targeted serum IgG4 testing and skin biopsy, ultimately confirming the diagnosis of primary IgG4-RSD. After treatment with a standardized regimen of glucocorticoids combined with azathioprine as a steroid-sparing agent, the skin lesions significantly improved. At the 2-month follow-up after discharge, no new skin lesions developed, pre-existing lesions had largely healed, and serum IgG4 levels returned to normal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Primary IgG4-RSD is rare and diagnostically challenging, as it can mimic a wide range of diseases and its pathogenesis remains incompletely understood. A definitive diagnosis requires markedly elevated serum IgG levels, characteristic histopathological findings, and rigorous exclusion of mimicking disorders. Additionally, the condition tends to relapse during treatment. Therefore, enhancing clinicians\u2019 understanding of IgG4-RD is crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1850129","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:38:16Z","timestamp":1782797896000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of primary IgG4-related skin disease presenting initially with skin papules and abscesses"],"prefix":"10.3389","volume":"17","author":[{"given":"Xing-Yue","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Wei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Lan","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jia","family":"Zhi","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2017.01.001","article-title":"Interpretation of the first international consensus guidance on the management and treatment of IgG4-related disease","volume":"9","author":"Chen","year":"2015","journal-title":"Chin J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.21037\/tbcr-20-65","article-title":"Chinese expert consensus on the diagnosis and treatment of IgG4-related disease","volume":"60","author":"Zhang","year":"2021","journal-title":"Chin J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1155\/2013\/532612","article-title":"Omprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011","volume":"22","author":"Umehara","year":"2012","journal-title":"Mod Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2013.2113","article-title":"IgG4-related skin disease","volume":"171","author":"Tokura","year":"2014","journal-title":"Br J Dermatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/j.semdp.2023.11.005","article-title":"Challenges and pitfalls in the diagnosis of IgG4-related disease","volume":"41","author":"Bateman","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3892\/etm.2021.9633","article-title":"Visual impairment in immunoglobulin G4-related disease: a case report","volume":"21","author":"Wang","year":"2021","journal-title":"Exp Ther Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pan.2016.12.003","article-title":"International consensus for the treatment of autoimmune pancreatitis","volume":"17","author":"Okazaki","year":"2017","journal-title":"Pancreatology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/259408","article-title":"Development of an igG4-RD responder index","volume":"2012","author":"Carruthers","year":"2012","journal-title":"Int J Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2020.1859710","article-title":"Research Program for Intractable Disease by the Ministry of Health, Labor and Welfare (MHLW) Japan. The 2020 revised comprehensive diagnostic (RCD) criteria for IgG4-RD","volume":"31","author":"Umehara","year":"2021","journal-title":"Mod Rheumatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-443-23947-2.00043-6","article-title":"Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations","volume":"64","author":"Stone","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaad.2016.01.046","article-title":"Cutaneous manifestations of IgG4-related disease (RD): a systematic review","volume":"75","author":"Charrow","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-012-0786-7","article-title":"Investigations of IgG4-related disease involving the skin","volume":"23","author":"Yamada","year":"2013","journal-title":"Mod Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.2625","article-title":"IgG4-related skin disease successfully treated by thalidomide: a report of 2 cases with emphasis on pathological aspects","volume":"149","author":"Ingen-Housz-Oro","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12325","article-title":"IgG4-related skin lesions: case report and review of the literature","volume":"39","author":"Kempeneers","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(19)30017-7","article-title":"Management of igG4-related disease","volume":"1","author":"Zhang","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s0151-9638(16)30001-1","article-title":"Quoi de neuf en dermatologie clinique? [What's new in clinical dermatology","volume":"142","author":"Valeyrie-Allanore","year":"2015","journal-title":"Ann Dermatol Venereol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen","year":"2019","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes358","article-title":"Necessity of early intervention for IgG4-related disease\u2014delayed treatment induces fibrosis progression","volume":"52","author":"Shimizu","year":"2013","journal-title":"Rheumatol (Oxford)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102354","article-title":"Characteristics and prognosis of IgG4-related periaortitis\/periarteritis: a systematic literature review","volume":"18","author":"Akiyama","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1038\/s41598-017-06520-5","article-title":"Efficacy of cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids","volume":"7","author":"Yunyun","year":"2017","journal-title":"Sci Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0534-6","article-title":"IgG4-related disease: beyond glucocorticoids","volume":"35","author":"Akiyama","year":"2018","journal-title":"Drugs Aging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1532560","article-title":"Effectiveness of tacrolimus on IgG4-related disease","volume":"29","author":"Takanashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40136-2_27","article-title":"A CD8\u03b1- subset of CD4+SLAMF7+ Cytotoxic T cells is expanded in patients with igG4-related disease and decreases following glucocorticoid treatment","volume":"70","author":"Della-Torre","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez380","article-title":"Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis","volume":"59","author":"Omar","year":"2020","journal-title":"Rheumatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.39132","article-title":"International consensus guidance statement on the management and treatment of igG4-related disease","volume":"67","author":"Khosroshahi","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183844","article-title":"Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients","volume":"12","author":"Ebbo","year":"2017","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2023.2195627","article-title":"IgG4-related disease: advances in pathophysiology and treatment","volume":"19","author":"Peyronel","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224487","article-title":"Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial","volume":"83","author":"Peng","year":"2024","journal-title":"Ann Rheumatic Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1850129\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T05:38:21Z","timestamp":1782797901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1850129\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1850129"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1850129","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"article-number":"1850129"}}